First-quarter sales rose 14.6% year on year and operating profit rose 34.1%, putting earnings ahead of schedule against the full-year forecast. In FY2027-H1, the focus will be how much sales can be built while maintaining this high profit margin.
All recorded disclosures and news since the latest annual or semiannual filing. Switching watchpoints keeps the full history. Select an item to inspect its source.2026-06-12 〜 2026-11-04 · 14 of 14 items
Scroll the timeline →
Can first-quarter sales of ¥31,087 million maintain a 26.8% progress rate against the full-year forecast of ¥116,000 million?
Can first-quarter operating profit of ¥4,751 million maintain a 41.3% progress rate against the full-year forecast of ¥11,500 million?
Can FY2027-H1 sales exceed the prior-year figure of ¥47,710 million?
Can FY2027-H1 operating profit exceed the prior-year figure of ¥4,687 million?
Will the full-year forecasts of ¥116,000 million in sales and ¥11,500 million in operating profit be maintained?
The company's ongoing themes and initiatives this watchpoint touches on.
First-quarter sales for the fiscal year ending March 2027 were ¥31,087 million, operating profit was ¥4,751 million, ordinary profit was ¥5,229 million, and net profit attributable to owners of the parent was ¥3,729 million. Year on year, sales rose 14.6%, operating profit 34.1%, ordinary profit 52.7%, and net profit 37.6%. The operating margin also increased from approximately 13.1% in the prior-year quarter to approximately 15.3%.
The full-year forecasts are sales of ¥116,000 million, operating profit of ¥11,500 million, ordinary profit of ¥11,000 million, and net profit of ¥7,400 million. First-quarter progress was 26.8% for sales, compared with 41.3% for operating profit, 47.5% for ordinary profit, and 50.4% for net profit, with earnings progress substantially ahead of sales. Prior-year results were sales of ¥111,822 million and operating profit of ¥10,878 million, implying forecast growth of 3.7% in sales and 5.7% in operating profit this fiscal year.
GGS's targets for the final year of its plan include sales of ¥120,000 million, operating profit of ¥10,800 million, overseas sales of ¥90,000 million, and an overseas sales ratio of 75%. The current company forecast is ¥700 million above the plan for operating profit but ¥4,000 million below it for sales. Profit-margin improvement is therefore ahead of plan, while sales remain below the scale target.
The agrochemicals business is seasonal, with demand concentrated in particular quarters. Previous disclosures stated that sales and profit are concentrated in the fourth quarter, from January to March. It is therefore not appropriate to simply extrapolate the first-quarter operating margin for the full year. In FY2027-H1, we will monitor whether sales of ¥47,710 million and operating profit of ¥4,687 million in the prior-year period can be exceeded, and whether the improvement in first-quarter profitability is being reproduced through prices, product mix, and cost improvements rather than volume growth alone. The first-quarter financial summary did not disclose sales by region or profit contributions by factor.
¥ millions
In the first quarter, operating profit growth outpaced sales growth, driving an improvement in margins.
Select a value or step to inspect its source.
Ordered by date. Disclosures and financial records differ from news and company threads; open each source to inspect it.
2026-11-10 · Awaiting publication
· Awaiting publication
The prior-year comparison for this event
2025-11-10 disclosed · In ¥ millions; each quarter is cumulative from the start of the fiscal year. EPS is in yen.
Latest available: FY2027 Q1
Net salesBusiness scale
47,710JPY m
↗ +21.9% YoYOperating profitCore earnings
4,687JPY m
↗ +355.5% YoYNewest first. The highlighted column is this event’s comparison. YoY uses the same period and accounting basis.
| Metric | FY2027 Q1 | FY2026 full year | FY2026 Q3 | FY2026 Q2Comparison | FY2026 Q1 | FY2025 full year | FY2025 Q3 | FY2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales | 31,087↗ +14.6% YoY | 111,822↗ +11.9% YoY | 70,360↗ +14.6% YoY | 47,710↗ +21.9% YoY | 27,133YoY unavailable | 99,966YoY unavailable | 61,374YoY unavailable | 39,129YoY unavailable |
| Operating profit | 4,751↗ +34.1% YoY | 10,878↗ +26.8% YoY | 5,844↗ +60.6% YoY | 4,687↗ +355.5% YoY | 3,542YoY unavailable | 8,576YoY unavailable | 3,639YoY unavailable | 1,029YoY unavailable |
| Ordinary profit | 5,229↗ +52.7% YoY | 10,527↗ +48.6% YoY | 5,856↗ +91.3% YoY | 4,661↗ +798.1% YoY | 3,425YoY unavailable | 7,086YoY unavailable | 3,061YoY unavailable | 519YoY unavailable |
| Net income | 3,729↗ +37.7% YoY | 7,228↗ +206.8% YoY | 3,989↗ +89.6% YoY | 3,372↗ +443.9% YoY | 2,709YoY unavailable | 2,356YoY unavailable | 2,104YoY unavailable | 620YoY unavailable |
| Earnings per share | 47.61↗ +37.5% YoY | 92.32↗ +207.1% YoY | 50.95↗ +89.9% YoY | 43.09↗ +444.8% YoY | 34.63YoY unavailable | 30.06YoY unavailable | 26.83YoY unavailable | 7.91YoY unavailable |